Strs Ohio Sells 19,200 Shares of Ligand Pharmaceuticals Inc. (LGND)

Strs Ohio reduced its holdings in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 91.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 1,700 shares of the biotechnology company’s stock after selling 19,200 shares during the period. Strs Ohio’s holdings in Ligand Pharmaceuticals were worth $232,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. lifted its position in Ligand Pharmaceuticals by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,741,818 shares of the biotechnology company’s stock valued at $211,457,000 after acquiring an additional 54,200 shares during the period. Janus Henderson Group PLC lifted its position in Ligand Pharmaceuticals by 26.7% during the 3rd quarter. Janus Henderson Group PLC now owns 754,692 shares of the biotechnology company’s stock valued at $102,751,000 after acquiring an additional 159,201 shares during the period. Conestoga Capital Advisors LLC lifted its position in Ligand Pharmaceuticals by 13.1% during the 4th quarter. Conestoga Capital Advisors LLC now owns 489,830 shares of the biotechnology company’s stock valued at $67,072,000 after acquiring an additional 56,705 shares during the period. Stephens Investment Management Group LLC lifted its position in Ligand Pharmaceuticals by 0.7% during the 3rd quarter. Stephens Investment Management Group LLC now owns 451,228 shares of the biotechnology company’s stock valued at $61,435,000 after acquiring an additional 2,950 shares during the period. Finally, Ameriprise Financial Inc. lifted its position in Ligand Pharmaceuticals by 8.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 383,919 shares of the biotechnology company’s stock valued at $52,272,000 after acquiring an additional 29,620 shares during the period.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) opened at $152.42 on Tuesday. The company has a quick ratio of 0.95, a current ratio of 0.97 and a debt-to-equity ratio of 0.05. The stock has a market cap of $3,167.30, a PE ratio of 220.90, a price-to-earnings-growth ratio of 1.61 and a beta of 1.07. Ligand Pharmaceuticals Inc. has a twelve month low of $95.08 and a twelve month high of $170.30.

A number of research analysts recently issued reports on LGND shares. HC Wainwright set a $157.00 price target on shares of Ligand Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, October 18th. Roth Capital set a $158.00 price target on shares of Ligand Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, November 13th. Craig Hallum reissued a “buy” rating and set a $170.00 price target (up from $160.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday, November 15th. Deutsche Bank cut shares of Ligand Pharmaceuticals from a “hold” rating to a “sell” rating and set a $105.00 price target for the company. in a research report on Monday, November 20th. Finally, Zacks Investment Research cut shares of Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 30th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $150.83.

In other Ligand Pharmaceuticals news, Director Stephen L. Sabba sold 925 shares of Ligand Pharmaceuticals stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $137.25, for a total value of $126,956.25. Following the completion of the transaction, the director now directly owns 26,985 shares of the company’s stock, valued at $3,703,691.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John L. Higgins sold 5,269 shares of Ligand Pharmaceuticals stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $142.53, for a total transaction of $750,990.57. Following the completion of the transaction, the chief executive officer now directly owns 143,542 shares of the company’s stock, valued at $20,459,041.26. The disclosure for this sale can be found here. Insiders sold 70,852 shares of company stock valued at $10,915,823 over the last ninety days. Corporate insiders own 8.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Strs Ohio Sells 19,200 Shares of Ligand Pharmaceuticals Inc. (LGND)” was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.themarketsdaily.com/2018/02/13/strs-ohio-sells-19200-shares-of-ligand-pharmaceuticals-inc-lgnd.html.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Inc. (NASDAQ:LGND).

Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply